Abstract Number: PB1949
Meeting: ISTH 2020 Congress
Background: Neointimal hyperplasia is an important clinical entity in vascular surgery because it limits the long- term effectiveness of surgical and endovascular interventions. Neointimal hyperplasia is usually defined in an artery as thickening of the intimal layer after an injury such as angioplasty, stenting or surgical repair. Neointimal hyperplasia is also used to describe the thickening of venous and prosthetic bypass grafts that leads to reduced lumen diameter and flow and, ultimately, graft occlusion and thrombosis.
Aims: In this study, we aimed to investigate the effect of the low- level blue laser- mediated photodynamic therapy on neointimal hyperplasia reduction accompanied by lipid- based encapsulated methotrexate nanoparticles administration in the rabbit model of the carotid artery neointimal hyperplasia.
Methods: Endothelial denaturation of the right common carotid artery was performed by ballooning in New Zealand white rabbits. After 4 weeks, histopathology results showed the formation of the neointimal hyperplasia in all of the rabbits’ arteries. Then treatment group underwent catheter- based low- level blue laser (ƛ= 417 nm, E= 150 J/cm2)- mediated photodynamic therapy accompanied by lipid- based encapsulated methotrexate (10 mg/Kg) nanoparticles administration.
Results: Results from histopathology, B- mode and color Doppler ultrasonography showed a significant reduction in the mean value for blood mean velocity, smooth muscle cells density in the neointima layer, wall mean thickness and percentage of luminal cross- sectional area of stenosis and significant increase in the mean value for blood volume flow at the stenotic region in the treatment group compared with the other groups (P>0.05).
Conclusions: Enhanced anti- inflammatory effect of methotrexate – induced by catheter- based low- level blue laser photodynamic therapy, can cause to the smooth muscle cells density reduction and significantly dilate the luminal cross- sectional area of stenosis. This protocol may be a potential treatment to neointimal hyperplasia.
To cite this abstract in AMA style:Mehrad H, Foletti A. Neointimal Hyperplasia Regression using Lipid- Based Encapsulated Methotrexate Nanoparticles- Mediated Catheter- Based Low- Level Blue Laser Photodynamic Therapy [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/neointimal-hyperplasia-regression-using-lipid-based-encapsulated-methotrexate-nanoparticles-mediated-catheter-based-low-level-blue-laser-photodynamic-therapy/. Accessed January 21, 2022.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/neointimal-hyperplasia-regression-using-lipid-based-encapsulated-methotrexate-nanoparticles-mediated-catheter-based-low-level-blue-laser-photodynamic-therapy/